These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results Terminated 2006-000314-20 A randomized placebo-controlled clinical trial of topical photodynamic therapy with a nanoemulsion formulation of 5-aminolevulinic acid for the treatment of actinic keratosis 2007-03-12 due-trials
Completed, but no date 2006-006653-27 Phase IIa, single-center, randomized, double-blind, vehicle-controlled study to determine the efficacy and safety/tolerability of a topical riluzole formulation in patients with atopic eczema bad-data
Reported results 2007-003371-39 A randomized, double-blind, phase III multicenter study evaluating the safety and efficacy of BF-200 ALA versus placebo in the treatment of actinic keratosis when using PDT 2008-12-09 due-trials
Listed as ongoing, but also has a completion date and reported results 2007-006854-24 A randomized, observer blind, multinational phase III study to evaluate the safety and efficacy of a nanoemulsion gel formulation BF-200 ALA, in comparison with Metvix® and placebo, for the treatment ... 2010-05-11 bad-data
Not reported 2007-007037-39 A Phase II Proof-of-Concept, Randomized, Double-blind, Vehicle-controlled Study, Including an Open-label Comparison to an Active Control, To Assess the Efficacy and Safety/Tolerability of Topical Rilu... 2009-01-23 due-trials
Reported results 2013-002510-12 A randomized, double-blind, phase III multi-center study to evaluate the safety and efficacy of BF-200 ALA (Ameluz®) versus placebo in the field-directed treatment of mild to moderate actinic keratosi... 2015-04-24 due-trials
Ongoing, reported early 2013-003241-42 A randomized, observer blind, multinational phase III study to evaluate the safety and efficacy of BF-200 ALA (Ameluz®) in comparison to Metvix® in the treatment of non-aggressive basal cell carcinoma... not-yet-due
Reported results 2015-004382-83 A randomized, observer-blind, intra-individual phase III study to evaluate the safety and efficacy of BF 200 ALA (Ameluz®) in combination with daylight-PDT (photodynamic therapy) in comparison with Me... 2017-09-19 due-trials
Ongoing 2017-000486-72 A randomized, double-blind, intra-individual, multi-center phase III study to evaluate the safety and efficacy of BF 200 ALA (Ameluz®) versus placebo in the treatment of mild to severe actinic keratos... not-yet-due